查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
到 2030 年孤儿药市场预测：按疾病类型、药物类型、销售、药物、配销通路和地区进行的全球分析
市场调查报告书
商品编码
1383503

到 2030 年孤儿药市场预测：按疾病类型、药物类型、销售、药物、配销通路和地区进行的全球分析

Orphan Drugs Market Forecasts to 2030 - Global Analysis By Disease Type, Drug Type, Sale, Drug, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球孤儿药市场规模为 1,758 亿美元，预计到 2030 年将达到 4,455 亿美元，预测期内年复合成长率为 14.2%。

用于识别和治疗罕见疾病的药物称为孤儿药。孤儿药物可以有效治疗多种疾病，包括癌症、代谢性疾病、血液疾病、慢性疾病、进行性疾病、病毒性疾病和神经系统疾病。孤儿药通常针对罕见疾病的特定遗传或分子异常采取有针对性的方法。其结果是提供更准确和有效的治疗方案，从而改善患者的治疗结果，包括提高存活率、症状控制和整体生活品质。

根据遗传和罕见疾病（GARD）资讯中心的数据，美国已知的罕见疾病超过10,000种，影响着十分之一的人，美国有3000万人。

提高对该病的认识

增加疾病知识是推动孤儿药市场的一个主要因素，因为它提高了人们对罕见疾病的认识并推动了宣传、资助和研究。此外，患者、医疗保健专业人员和倡导团体意识的提高增加了对有效治疗方法的需求，并激励製药公司资助孤儿药的研发。最终，我们将透过提供更容易获得的专业治疗方法来扩大市场并改善罕见疾病患者的生活。这还可以带来财政支持、法规激励和加强伙伴关係。

初期成本高

开发治疗罕见疾病的药物的过程需要广泛的研究、临床试验和法规程序，成本高昂。此外，孤儿药通常很昂贵，因为这些费用必须由药品价格来支付。它们的高成本使得难以广泛提供且价格合理的孤儿药，并可能给保险公司、医疗保健系统和患者带来挑战。因此，患者的治疗选择有限，罕见疾病患者未满足的医疗需求可能无法解决。

法规奖励的演变

这些激励措施包括扩大市场独占权、税收优惠和更快的核准程序。这些激励措施透过降低财务风险和缩短上市时间来激励製药公司投资孤儿药开发。此外，此类激励措施使这些项目在财务上更加可行，从而促进创新，让更多人能够满足罕见疾病患者未满足的医疗需求，孤儿药变得可用。製药公司和罕见疾病患者都可以从双赢的局面中受益。因此，政府法规提供有利的奖励，鼓励罕见疾病治疗方法的开发，是推动孤儿药产业的主要因素。

与有限可能性相关的风险

有限的市场潜力可能会阻碍公司开拓孤儿药市场，导致罕见疾病患者的治疗选择减少，并延迟获得创新治疗方法。此外，被称为孤儿药的药物是为了治疗仅影响少数人的罕见疾病而创建的。由于受影响的患者数量较少，这些药物的市场规模比针对更常见疾病的药物要小。此外，製药公司可能会发现投资孤儿药研发在经济上并不可取，进而为市场扩张带来障碍。

COVID-19 的影响

COVID-19 的爆发扰乱了世界各地医疗领域的工作流程。许多行业，包括一些与医疗保健相关的子行业，因这种疾病而被迫暂时关闭。孤儿药市场也正在经历负成长，包括筛检服务减少、接触专家的机会减少、治疗中断、大多数行业的业务限制、学术机构和研究缺乏资金以及许多问题在起作用，包括暂时关闭学术机构、供应链中断以及提供所需服务和售后服务的困难。

预计肿瘤学领域在预测期内将是最大的。

肿瘤学领域估计占最大份额。孤儿药在肿瘤疾病的治疗中扮演重要角色。专门用于治疗仅影响少数患者的罕见疾病的药物称为孤儿药。即使个别癌症类型不是罕见疾病，癌症类型中的某些亚型或突变也可能被归类为罕见疾病。孤儿药针对导致癌症发展和扩散的特定遗传异常或分子途径。有利的法规激励措施、向精准医疗的转变以及罕见癌症亚型盛行率的增加正在推动肿瘤孤儿药物市场显着增长。

生技药品产业预计在预测期内年复合成长率最高

预计生技药品领域将在预测期内出现良好的成长。对于患者数量较少的罕见疾病，可以开发生物製药来针对导致疾病的潜在遗传异常或分子途径。这种集中的方法减少了可能的副作用并提高了治疗效果。单株抗体是已开发的生物製药之一。单株抗体特异性结合癌细胞上的某些蛋白质，导致免疫系统攻击肿瘤。孤儿药市场正在开发和核准用于治疗罕见疾病（包括罕见癌症）的生物製药越来越多。

比最大的地区

由于工业基础设施的成长、可支配所得的增加以及有利的政府政策，亚太地区在预测期内占据了最大的市场占有率。此外，亚太地区的临床试验成长预计将快于美国和欧洲，有助于该地区的市场扩张。此外，政府配合措施扩大肿瘤中心和社区健康中心的数量预计将扩大开发中国家孤儿药的供应。

复合年复合成长率最高的地区：

由于主要市场参与者和大量罕见疾病患者的存在，预计北美在预测期内将实现盈利增长。此外，孤儿药核准数量的增加、处于市场开拓阶段的孤儿药数量的增加以及该地区孤儿药支出的增加是推动北美地区孤儿药市场的其他因素。一个促成因素。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和年复合成长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第1章执行摘要

第2章前言

  • 概述
  • 利害关係人
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第3章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球孤儿药市场：依疾病类型

  • 肿瘤性疾病
    • 胰臟癌
    • 急性骨髓性白血病
    • 多发性骨髓瘤
    • 卵巢癌
    • 肾臟细胞癌
  • 代谢性疾病
    • 猎人症候群
    • 高雪氏症
    • 法布瑞氏症
    • 甲状旁腺功能低下症
  • 血液和免疫疾病
    • 血友病
    • 遗传性血管性水肿
  • 感染疾病
  • 神经系统疾病
    • 亨丁顿舞蹈症
    • 阿兹海默症

第6章全球孤儿药市场：依药物类型

  • 非生技药品
  • 生技药品

第7章全球孤儿药市场：依销售额分类

  • 处方
  • 通用的

第8章全球孤儿药市场：依药物分类

  • 立树山
  • Revlimid
  • 伊布维察
  • 奥狄沃
  • 达札雷克斯
  • 波马主义者
  • 其他药品

第9章全球孤儿药市场：依配销通路

  • 网路药房
  • 医院药房
  • 零售药房
  • 其他配销通路

第10章全球孤儿药市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第11章进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第12章公司简介

  • Bayer AG
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Bristol-Myers Squibb Company
  • Amgen Inc.
  • Novo Nordisk A/S
  • Alexion Pharmaceuticals Inc.
  • GlaxoSmithKline plc
  • AstraZeneca
  • Celgene Corporation
  • Mylan
  • Biogen
  • Merck KGaA
  • Takeda Pharmaceutical Company Limited
  • Eli Lilly and Company
  • Shire Pharmaceutical
Product Code: SMRC24351

According to Stratistics MRC, the Global Orphan Drugs Market is accounted for $175.8 billion in 2023 and is expected to reach $445.5 billion by 2030 growing at a CAGR of 14.2% during the forecast period. Drugs used to identify and treat uncommon medical conditions are known as orphan drugs. Numerous oncological, metabolic, hematologic, chronic, progressive, viral, and neurological illnesses can be effectively treated with them. Orphan medications often employ a targeted approach, concentrating on the particular genetic or molecular abnormalities that underlie a rare disease. This results in more precise and effective treatment options, leading to improved patient outcomes, including increased survival rates, symptom management, and overall quality of life.

According to the Genetic and Rare Diseases (GARD) Information Center, there are more than 10,000 known rare diseases in the U.S. that affect about 1 in 10 people or 30 million people in the U.S.

Market Dynamics:

Driver:

Rise in disease awareness

Growing knowledge of diseases is a major factor driving the market for orphan medications since it makes rare diseases better recognized, which encourages advocacy, funding, and research. Moreover, an increase in patient, healthcare professional and advocacy group awareness drives up the need for efficient therapies, which in turn motivates pharmaceutical corporations to fund research and development of orphan drugs. In the end, it expands the market and enhances the lives of people with rare diseases by making specialized therapies more accessible. Therefore, it also results in increased support for funding, regulatory incentives, and partnerships.

Restraint:

High initial costs

The process of creating medications for uncommon diseases can be costly due to the extensive research, clinical trials, and regulatory procedures involved. Additionally, orphan medications are generally costly since these expenses must be covered by drug prices. It can be difficult to deliver rare disease therapies that are both widely available and reasonably priced due to the high expenses, which can also pose access challenges for insurers, healthcare systems, and patients. Hence, this can leave patients with limited treatment options and hinder progress in addressing the unmet medical needs of individuals with rare diseases.

Opportunity:

Developments in regulatory incentives

Extended market exclusivity, tax rebates, and accelerated approval procedures are all included in these incentives. They incentivize pharmaceutical companies to spend money on the development of orphan drugs by lowering financial risks and accelerating time to market. Furthermore, these kinds of incentives make these ventures more financially viable, which in turn encourage innovation and make more orphan medications available to meet the unmet medical requirements of people with rare diseases. Pharmaceutical businesses and those with rare illnesses benefit from this in a win-win scenario. Hence, government regulations that provide favourable incentives to encourage the development of therapies for rare diseases are a major factor driving the orphan drug industry.

Threat:

Risks associated with limited potential

The limited market potential can discourage companies from pursuing orphan drug development, resulting in fewer treatment options for patients with rare diseases and potential delays in accessing innovative therapies. Moreover, drugs known as orphans are created to treat uncommon conditions that only a tiny number of people have. The market for these medications is less than that of medications for more prevalent disorders because of the small number of patients. Furthermore, pharmaceutical corporations may find it financially undesirable to invest in the research and development of orphan medications as a result, which is a drawback of the market's expansion.

COVID-19 Impact

The outbreak of COVID-19 has disrupted workflows in the health care sector around the world. Numerous industries, including some healthcare-related sub-sectors, have been forced to temporarily close their doors due to the disease. The market for orphan drugs has also experienced negative growth, which can be linked to a number of issues, including a drop in screening services, a decrease in access to specialists, treatment interruptions, restricted operations in the majority of industries, insufficient funding for academic institutions and research, the temporary closure of significant academic institutions, supply chain disruptions, and difficulties delivering necessary or post-sales services.

The oncological diseases segment is expected to be the largest during the forecast period

The oncological diseases segment is estimated to hold the largest share. Orphan drugs play a crucial role in the treatment of oncological diseases. A medication created especially to treat uncommon diseases that only affect a small number of patients is known as an orphan drug. Certain subtypes or mutations within a cancer type can be classified as rare diseases, even though individual cancer types might not be. These orphan medications target particular genetic defects or molecular pathways that contribute to the development and spread of cancer. Due to favourable regulatory incentives, a shift towards precision medicine, and the rising prevalence of rare cancer subtypes, the market for orphan drugs for oncological diseases has experienced significant growth.

The biologics segment is expected to have the highest CAGR during the forecast period

The biologics segment is anticipated to have lucrative growth during the forecast period. Biologics can be created to target the underlying genetic abnormalities or molecular pathways that cause the disease in the case of orphan diseases, where the patient population is small. This focused approach lowers possible side effects and improves treatment efficacy. One sort of biologic that has been developed is the monoclonal antibody. It binds specifically to certain proteins on cancer cells, causing the immune system to attack the tumor. The orphan drug market has witnessed a growing number of biologic drugs being developed and approved for rare diseases, including rare forms of cancer.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period owing to the growing infrastructure of industries, rising disposable incomes, and favourable government policies in the region. Furthermore, clinical trial growth in Asia-Pacific is anticipated to accelerate beyond that of the United States and Europe, contributing to the region's market expansion. Moreover, it is anticipated that an increase in government initiatives to expand the number of oncology and community health centers will broaden the availability of orphan medications in developing nations.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period, due to the presence of major market players and a large population of patients with orphan diseases. Additionally, a growing number of orphan product approvals, a sizable number of orphan drugs in the development stage, and rising orphan drug spending in the area are the other factors driving the orphan drug market in the North American region.

Key players in the market

Some of the key players in the Orphan Drugs Market include: Bayer AG, Novartis AG, F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Amgen Inc., Novo Nordisk A/S, Alexion Pharmaceuticals Inc., GlaxoSmithKline plc, AstraZeneca, Celgene Corporation, Mylan, Biogen, Merck KGaA, Takeda Pharmaceutical Company Limited, Eli Lilly and Company and Shire Pharmaceutical.

Key Developments:

In March 2023, F. Hoffmann-La Roche Ltd: Roche announces collaboration with Lilly to enhance early diagnosis of Alzheimer's disease.

In January 2022, Amgen and Generate Biomedicines announced a research collaboration agreement to discover and create protein therapeutics for five clinical targets across several therapeutic areas and multiple modalities.

Disease Types Covered:

  • Oncological Diseases
  • Metabolic Diseases
  • Hematologic & Immunologic Diseases
  • Infectious diseases
  • Neurological diseases

Drug Types Covered:

  • Non-Biologics
  • Biologics

Sales Covered:

  • Prescribed
  • Generics

Drugs Covered:

  • Rituxan
  • Revlimid
  • Imbruvica
  • Opdivo
  • Darzalex
  • Pomalyst
  • Other Drugs

Distribution Channels Covered:

  • Online Pharmacies
  • Hospital Pharmacies
  • Retail Pharmacies
  • Other Distribution Channels

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Orphan Drugs Market, By Disease Type

  • 5.1 Introduction
  • 5.2 Oncological Diseases
    • 5.2.1 Pancreatic Cancer
    • 5.2.2 Acute Myeloid Leukemia
    • 5.2.3 Multiple Myeloma
    • 5.2.4 Ovarian Cancer
    • 5.2.5 Renal Cell Carcinoma
  • 5.3 Metabolic Diseases
    • 5.3.1 Hunter Syndrome
    • 5.3.2 Gaucher Disease
    • 5.3.3 Fabry Disease
    • 5.3.4 Hypoparathyroidism
  • 5.4 Hematologic & Immunologic Diseases
    • 5.4.1 Hemophilia
    • 5.4.2 Hereditary Angioedema
  • 5.5 Infectious diseases
  • 5.6 Neurological diseases
    • 5.6.1 Huntington's Disease
    • 5.6.2 Alzheimer's Disease

6 Global Orphan Drugs Market, By Drug Type

  • 6.1 Introduction
  • 6.2 Non-Biologics
  • 6.3 Biologics

7 Global Orphan Drugs Market, By Sale

  • 7.1 Introduction
  • 7.2 Prescribed
  • 7.3 Generics

8 Global Orphan Drugs Market, By Drug

  • 8.1 Introduction
  • 8.2 Rituxan
  • 8.3 Revlimid
  • 8.4 Imbruvica
  • 8.5 Opdivo
  • 8.6 Darzalex
  • 8.7 Pomalyst
  • 8.8 Other Drugs

9 Global Orphan Drugs Market, By Distribution Channel

  • 9.1 Introduction
  • 9.2 Online Pharmacies
  • 9.3 Hospital Pharmacies
  • 9.4 Retail Pharmacies
  • 9.5 Other Distribution Channels

10 Global Orphan Drugs Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Bayer AG
  • 12.2 Novartis AG
  • 12.3 F. Hoffmann-La Roche Ltd
  • 12.4 Bristol-Myers Squibb Company
  • 12.5 Amgen Inc.
  • 12.6 Novo Nordisk A/S
  • 12.7 Alexion Pharmaceuticals Inc.
  • 12.8 GlaxoSmithKline plc
  • 12.9 AstraZeneca
  • 12.10 Celgene Corporation
  • 12.11 Mylan
  • 12.12 Biogen
  • 12.13 Merck KGaA
  • 12.14 Takeda Pharmaceutical Company Limited
  • 12.15 Eli Lilly and Company
  • 12.16 Shire Pharmaceutical

List of Tables

  • Table 1 Global Orphan Drugs Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Orphan Drugs Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 3 Global Orphan Drugs Market Outlook, By Oncological Diseases (2021-2030) ($MN)
  • Table 4 Global Orphan Drugs Market Outlook, By Pancreatic Cancer (2021-2030) ($MN)
  • Table 5 Global Orphan Drugs Market Outlook, By Acute Myeloid Leukemia (2021-2030) ($MN)
  • Table 6 Global Orphan Drugs Market Outlook, By Multiple Myeloma (2021-2030) ($MN)
  • Table 7 Global Orphan Drugs Market Outlook, By Ovarian Cancer (2021-2030) ($MN)
  • Table 8 Global Orphan Drugs Market Outlook, By Renal Cell Carcinoma (2021-2030) ($MN)
  • Table 9 Global Orphan Drugs Market Outlook, By Metabolic Diseases (2021-2030) ($MN)
  • Table 10 Global Orphan Drugs Market Outlook, By Hunter Syndrome (2021-2030) ($MN)
  • Table 11 Global Orphan Drugs Market Outlook, By Gaucher Disease (2021-2030) ($MN)
  • Table 12 Global Orphan Drugs Market Outlook, By Fabry Disease (2021-2030) ($MN)
  • Table 13 Global Orphan Drugs Market Outlook, By Hypoparathyroidism (2021-2030) ($MN)
  • Table 14 Global Orphan Drugs Market Outlook, By Hematologic & Immunologic Diseases (2021-2030) ($MN)
  • Table 15 Global Orphan Drugs Market Outlook, By Hemophilia (2021-2030) ($MN)
  • Table 16 Global Orphan Drugs Market Outlook, By Hereditary Angioedema (2021-2030) ($MN)
  • Table 17 Global Orphan Drugs Market Outlook, By Infectious diseases (2021-2030) ($MN)
  • Table 18 Global Orphan Drugs Market Outlook, By Neurological diseases (2021-2030) ($MN)
  • Table 19 Global Orphan Drugs Market Outlook, By Huntington's Disease (2021-2030) ($MN)
  • Table 20 Global Orphan Drugs Market Outlook, By Alzheimer's Disease (2021-2030) ($MN)
  • Table 21 Global Orphan Drugs Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 22 Global Orphan Drugs Market Outlook, By Non-Biologics (2021-2030) ($MN)
  • Table 23 Global Orphan Drugs Market Outlook, By Biologics (2021-2030) ($MN)
  • Table 24 Global Orphan Drugs Market Outlook, By Sale (2021-2030) ($MN)
  • Table 25 Global Orphan Drugs Market Outlook, By Prescribed (2021-2030) ($MN)
  • Table 26 Global Orphan Drugs Market Outlook, By Generics (2021-2030) ($MN)
  • Table 27 Global Orphan Drugs Market Outlook, By Drug (2021-2030) ($MN)
  • Table 28 Global Orphan Drugs Market Outlook, By Rituxan (2021-2030) ($MN)
  • Table 29 Global Orphan Drugs Market Outlook, By Revlimid (2021-2030) ($MN)
  • Table 30 Global Orphan Drugs Market Outlook, By Imbruvica (2021-2030) ($MN)
  • Table 31 Global Orphan Drugs Market Outlook, By Opdivo (2021-2030) ($MN)
  • Table 32 Global Orphan Drugs Market Outlook, By Darzalex (2021-2030) ($MN)
  • Table 33 Global Orphan Drugs Market Outlook, By Pomalyst (2021-2030) ($MN)
  • Table 34 Global Orphan Drugs Market Outlook, By Other Drugs (2021-2030) ($MN)
  • Table 35 Global Orphan Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 36 Global Orphan Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 37 Global Orphan Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 38 Global Orphan Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 39 Global Orphan Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.